The potential options for gastric cancer are rapidly evolving based on new research into existing and emerging biomarkers. Learn about the current unmet need in gastric and gastroesophageal junction (GEJ) cancer, and how biomarkers have the potential to advance care for these patients.

 

 


An Oncologist with a Personal Touch

After his own cancer diagnosis, Dr. Mark Lewis, Intermountain Healthcare Director of GI Oncology, has made advancing cancer research a personal matter. Hear his thoughts on how and why the gastric and GEJ cancer landscape needs to evolve and the biomarkers that are driving new research.

Click to play

Click to play

Click to play

Gastric Cancer Media Resources

Early stage gastric and GEJ cancer frequently shows no symptoms, or the symptoms overlap with other gastric related conditions, making it difficult to detect. Learn more about the risk factors, signs, and symptoms.

  

New research is emerging around novel biomarkers that can uncover previously unidentified subsets of gastric and GEJ cancer patients. Learn more about what biomarkers are, why they are being explored and how they are being applied in the clinical landscape.

Back to the Gastric Cancer Hub Landing Page Back to the Astellas US Newsroom
Explore Biomarkers in Gastric Cancer

074-0593-PM 11/22 MAT-US-NON-2022-01013

Follow Us On Social Media
Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter